<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="236046">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005882</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067922</org_study_id>
    <secondary_id>1997-96</secondary_id>
    <secondary_id>NCI-P00-0150</secondary_id>
    <nct_id>NCT00005882</nct_id>
  </id_info>
  <brief_title>Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps</brief_title>
  <official_title>A Phase II Clinical Trial of a Randomized, Double-Blind, Placebo Controlled Clinical Trial of DFMO and Sulindac Against Various Endpoints of Colorectal Pathobiology in a Cohort of Individuals at Increased Risk of Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chao Family Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development or recurrence of cancer. The use of eflornithine and sulindac may be an
      effective way to prevent the development of colorectal cancer in patients who have had
      surgery to remove benign colorectal polyps.

      PURPOSE: Randomized, double-blinded, phase II trial to determine the effectiveness of
      eflornithine plus sulindac compared to a placebo in preventing colorectal cancer in patients
      who have had surgery to remove benign colorectal polyps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of eflornithine (DFMO) and sulindac vs placebo in modulating a
           panel of surrogate endpoint biomarkers (SEB) of particular relevance in colorectal
           neoplasia, including quantitative histopathology, uninduced apoptosis, proliferative
           (Ki67) and preneoplastic (CEA, sialyl-TN, p53, and bcl-2) features, and polyamine and
           PGE2 levels in patients with at least one previously resected colorectal adenoma.

        -  Determine the relationship between the modulation of SEB in flat mucosa and the
           development of interval incident colorectal adenomas in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to aspirin use (yes vs no) and participating center.

      Patients receive oral placebo daily for the first 4 weeks. Patients who are compliant and
      take the placebo 5 to 7 days each week are randomized to one of two treatment arms.

        -  Arm I: Patients receive oral sulindac and oral eflornithine (DFMO) daily.

        -  Arm II: Patients receive oral placebo daily. Treatment continues for 3 years in the
           absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: Approximately 240 patients (120 per treatment arm) will be accrued for
      this study within 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the efficacy of DFMO plus Sulindac versus placebo in modulating biomarkers of colorectal neoplasia.</measure>
    <time_frame>36 months post-randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>DFMO+sulindac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eflornithine plus sulindac</intervention_name>
    <description>Patients will be randomized to 36 months of treatment with either DFMO+sulindac or placebo.</description>
    <arm_group_label>DFMO+sulindac</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  At least 1 prior resected colorectal adenoma within the past 5 years

               -  At least 3 mm in size

          -  No personal or family history of familial adenomatous polyposis

        PATIENT CHARACTERISTICS:

        Age:

          -  40 to 80

        Performance status:

          -  SWOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Hematocrit at least 35%

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  AST and ALT no greater than 2 times normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

          -  No greater than 1+ protein, 0-3 casts, and 0-5 WBCs and RBCs in urine

        Gastrointestinal:

          -  No requirement for special diet or additives

          -  No diet that would preclude taking study medications

          -  No gastric or duodenal ulcer within the past year

          -  No inflammatory bowel disease

        Other:

          -  No more than 20 dB hearing loss for age at any frequency

          -  No prior or concurrent invasive cancer within the past 5 years except nonmelanomatous
             skin cancer, melanoma in situ, stage I cervical cancer, stage I colon cancer, or
             stage 0 chronic lymphocytic leukemia

          -  No severe metabolic disorder or other acute or chronic diseases

          -  No history of or predisposition to abnormal wound healing or repair

          -  No allergies to nonsteroidal anti-inflammatories or eflornithine

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent corticosteroids

        Radiotherapy:

          -  No concurrent radiotherapy

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No other concurrent nonsteroidal anti-inflammatories or anticoagulants administered
             on a regular or predictable intermittent basis

          -  No concurrent aspirin greater than 81 mg per day or 325 mg twice a week for
             cardiovascular disease prophylaxis

          -  No concurrent calcium supplements greater than 500 mg/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank L. Meyskens, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Loma Linda (Pettis)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Abstract A29: Rectal mucosal polyamine and PGE2 levels and risk of colorectal adenomas in a phase IIb/III trial of combination difluoromethylornithine (DFMO) plus sulindac Patricia A. Thompson, Betsy C. Wertheim, Jason A. Zell, Bonnie LeFleur, Wen-Pin Chen, Christine E. McLaren, Frank L. Meyskens, and Eugene W. Gerner Cancer Prev Res January 7, 2010 3:A29; doi:10.1158/1940-6207.PREV-09-A29</citation>
  </results_reference>
  <results_reference>
    <citation>Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun;1(1):32-8. doi: 10.1158/1940-6207.CAPR-08-0042.</citation>
    <PMID>18841250</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>June 2, 2000</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Vanessa Wong</investigator_full_name>
    <investigator_title>User Account Contact</investigator_title>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulindac</mesh_term>
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
